|
|
 |
A sunrise view in Taleqan - Alborz Province - Iran(photo by M.H.Azizi MD)
|
|
|
|
|
|
|
|
|
Archives of Iranian Medicine: 2011 and beyond
AIM will be published monthly from 2012 with an increased focus on preventive medicine and public health. In its 14th birthday, this switch from bimonthly publication, will complete the Journal’s 4-year transition from a quarterly journal. This change will not only allow us to present the recent advances in medical sciences in a more timely fashion to our readers, but also shorten the wait time for the authors, and has been made possible with the constant support and enthusiasm of our contributors and reviewers. More...
|
|
|
|
|
|
|
|
|
A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.
|
|
|
|
Call For Papers
Achieves of Iranian Medicine (AIM) is planning a series of special issues to publish state-of-the-art research and reviews in some of the most challenging fields of biomedical sciences. Manuscripts should focus on different aspects of human health and disease at regional and global levels, and are accepted both by invitation and through the usual submission process [link to Instructions to authors]. All manuscripts will undergo fast track peer review. The table below summarizes these special issues, along with the guest editors’ names and a tentative timeline. The definite submission and publication dates will depend on the number and quality of the submissions received. More information can be found on the specific webpage for each topic, or by contacting the guest editors.
| Topic |
Guest editor(s) |
Submission deadline* |
Publication date* |
| Diabetes and dyslipidemias |
Fereidoun Azizi, MD (azizi@endocrine.ac.ir) |
March 2013 |
-------------- |
| Chronic Liver Disease |
Shahin Merat, MD (merat@tums.ac.ir)
Hossein Poustchi, MD (poustchi@ams.ac.ir)
|
March 2013 |
-------------- |
| Upper GI Cancers |
Farhad Islami, MD PhD (farhad.islami@mssm.edu)
Arash Etemadi, MD PhD (arash.etemadi@nih.gov)
|
March 2013 |
July 2013 |
| Health System Performance |
Farshad Farzadfar, MD DSc (farshad.farzadfar@saphirnetwork.org) |
May 2013 |
September 2013 |
| Atherosclerosis |
Nizal Sarrafzadegan, MD (sarrafzadegan@med.mui.ac.ir ) |
July 2013 |
November 2013 |
* Dates are tentative and will depend on the number and quality of the manuscripts received. Please contact the journal or the guest editors to confirm the deadlines.
|
| |
|
|
|
Are the Serum Biomarkers Pepsinogen I and II Good Predictors for the Detection of Subjects with Atrophic Gastritis in Areas that have Different Gastric Cancer Incidence?
1 |
|
Authors' affiliations: 1,6,7,9,10 Digestive Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2Physiology Research Center, Department of Internal Medicine, KermanUuniversity of Medical Sciences, Kerman, Iran. 3Department of Internal Medicine, Yazd University of Medical Sciences, Yazd, Iran. 4,5,8Aras Clinic, Ardabil University of Medical Sciences, Ardabil, Iran.
•Corresponding author and reprints: Sadegh Massarrat MD, Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, 14117-13135 Tehran, Iran. Tel: +98-218-241-5300; Fax: +98-218-241-5400; E-mail: massarrat@ams.ac.ir
Accepted for publication: 27 February 2013
|
Download PDF Fulltext
|
|
Authors:
Ashraf Mohamadkhani1, Sodaif Darvish Moghaddam2, Hassan Salmanroghani3, Amin Allafsghari4, Abbas Yazdanbod5, Mahboobeh Mirzaei6, Arghavan Haj-sheykholeslami7, Jafar Bashiri8, Alireza Sadjadi9, *Sadegh Massarrat10,
|
|
|
|
Keywords:
Biomarker, Gastric cancer, Pepsinogen I, Pepsinogen II
|
|
BACKGROUND: Northern Iran (Ardabil) is characterized by a high gastric cancer (GC) rate, whereas Southern Iran (Kerman and Yazd) has a low GC rate. The aim of this study is to verify the potential for pepsinogen I and II to detect atrophic gastritis (AG) in both high and low risk populations for GC.
METHODS: Sera of blood donors and patients with GC from Ardebil, Kerman and Yazd were used to measure levels of pepsinogen I, II and H. pylori IgG antibody. GC rates in these cities were determined according to the Cancer Registry and upper gastrointestinal (GI) endoscopy results.
RESULTS: There were 449 subjects with an average age of 45 ± 15 years. The GC rate in the endoscopy units of the hospital in Ardabil was four times higher than Kerman or Yazd. The mean serum pepsinogen I levels did not differ between Ardabil (102 ± 42.6 µg/mL), Kerman (103.3 ± 49.8 µg/mL), and Yazd (111.7 ± 39 µg/mL). Pepsinogen II levels were: 8.1 ± 4.7 µg/mL (Ardabil), 7.5 ± 5.3 µg/mL (Kerman), and 7.6 ± 4.4 µg/mL (Yazd), which were not different. The H. pylori infection rates were: Ardabil (61%), Kerman (55%), and Yazd (73%). A low ratio of pepsinogen I to II (≤3) was seen in Ardabil (1.3%), Kerman (1.9%), and Yazd (0.0%), which was not significant. A total of 51.9% of GC patients from Ardabil had normal pepsinogen I (≥70 µg/mL) levels and pepsinogen I/II ratios that were >5.
CONCLUSION: Serum biomarkers pepsinogen I and II and their ratios are probably not sensitive predictors of AG in areas that have either a high or low GC prevalence. This finding is likely related to the lack of an association between GC and advanced AG.
|
|
|
|
ISSN:1029-2977
Article type:Original
|
|
| |
|
|